For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Description
The global Continuous Bioprocessing Market size is anticipated to expand from USD 133.9 million in 2022 to USD 443.1 million by 2029, registering a compound annual growth rate (CAGR) of 17.9% during the forecast period.
Continuous bioprocessing involves uninterrupted production of biopharmaceuticals using integrated systems, offering advantages such as scalability, cost savings, and consistent quality compared to traditional batch methods. It finds widespread application in the manufacturing of vaccines, monoclonal antibodies, and other biologics. Market growth is driven by the rising adoption of continuous processing approaches, technological advancements, increasing investments in biomanufacturing, and supportive government initiatives and policies worldwide. In addition, the growing prevalence of chronic diseases that necessitate biopharmaceutical treatment, such as cancer, is a key factor fueling demand.
However, stringent regulatory norms governing biopharmaceutical production and the high costs associated with continuous bioprocessing equipment and infrastructure pose challenges. The COVID-19 pandemic also disrupted research and development activities, delaying some projects in the short term.
Market Segmentation
The market is segmented based on various factors, including Product, Application, End-User, and Geography
Segmentation by Product
Filtration Systems and Consumables
Chromatography Systems and Consumables
Bioreactors
Sterilizers
Centrifuges
Others
Segmentation by Application
Commercial
Research and Development
Segmentation by End-User
Pharmaceutical and Biotechnology Companies
CDMOs and CROs
Academic and Research Institutes
Segmentation by Geography
North America - United States, Canada, Mexico
Europe - United Kingdom, Germany, France, Italy, Spain, and Rest of Europe
Asia-Pacific - China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific
Latin America - Brazil, Argentina, and Rest of Latin America
Middle East and Africa - GCC, South Africa, and Rest of Middle East and Africa
The research and development segment of the continuous bioprocessing market is projected to grow significantly due to increasing R&D expenditure, growing demand for biopharmaceuticals, new facility establishments, and technological advancements. Transcenta's breakthrough in March 2021, achieving high productivity in continuous perfusion cell culture, exemplifies the sector's progress. Collaborative efforts, like the USP and Phlow Corp. partnership, aim to promote wider adoption of continuous manufacturing. The establishment of dedicated biomanufacturing facilities for research and development activities will further drive market growth. The research and development segment will play a crucial role in overall market expansion.
The North American continuous processing market is driven by factors such as the burden of chronic diseases, product launches, strategic initiatives by market players, facility establishments, and technological advancements. The United States is expected to hold a significant market share, driven by the demand for biopharmaceuticals. A study suggests the economic attractiveness of continuous manufacturing in the US for oral solid dosage pharmaceuticals. These factors contribute to the anticipated growth of the continuous bioprocessing market.
Competitive Landscape
The continuous bioprocessing market is competitive, with a few major players holding significant market share. Notable companies include 3M Company, Bionet Servicios Tecnicos S.L., Bio-Rad Laboratories Inc., Danaher Corporation, Dover Corporation (Colder Products Company), Eppendorf SE, Fujifilm Corporation, Getinge AB, Merck KGaA, Repligen Corporation, Sartorius AG, and Thermo Fisher Scientific Inc.
Recent Industry Developments
CellulaREvolution raised GBP 1.75 million in February 2022 from notable investors, led by Happiness Capital. The funding will support their research and development efforts and strengthen their commercial team for the upcoming launch of their continuous cell culture technology.
In January 2022, WuXi Biologics invested EUR 325 million to enhance their biomanufacturing capabilities. The investment will be used to establish a state-of-the-art facility for continuous bioprocessing, improving efficiency and productivity.
Why Buy This Report?
Get a detailed picture of the Global Continuous Bioprocessing Market
Identify segments/areas to invest in over the forecast period in the Global Continuous Bioprocessing Market
Understand the competitive environment, the market's leading players
The market estimate for ease of analysis across scenarios in Excel format
Strategy consulting and research support for three months
Print authentication provided for the single-user license